Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
South Africa ushers in a new era for HIV

The country has developed the biggest programme of antiretroviral therapy in the world. Now scientists are exploring the long-term consequences of the drugs.

Published
14 July 2016
From
Nature
2016 recommendations for antiretroviral drugs for the treatment and prevention of HIV infection

In a report appearing in the July 12 issue of JAMA, an HIV/AIDS theme issue, Huldrych F. Gunthard, M.D., of University Hospital Zurich, Switzerland, and colleagues with the International Antiviral Society-USA panel, updated recommendations for the use of antiretroviral therapy in adults with established HIV infection, including when to start treatment, initial regimens, and changing regimens, along with recommendations for using antiretroviral drugs for preventing HIV among those at risk, including preexposure and postexposure prevention.

Published
13 July 2016
From
Science Daily
Gilead defeats AIDS activists who claimed the company manipulated patents

Gilead Sciences won a victory last week when a federal court judge tossed a lawsuit in which an AIDS activist group accused the drug maker of manipulating the patent system in order to thwart competition for its HIV medicines. At issue was tenofovir, or TDF, which Gilead is replacing with a modified version known as TAF.

Published
13 July 2016
From
STAT
Switching from tenofovir DF to TAF improves bone and kidney safety

People with HIV who switched from the older tenofovir disoproxil fumarate (TDF) formulation to tenofovir alafenamide (TAF) were more likely to maintain viral load suppression and showed improvements

Published
11 July 2016
By
Liz Highleyman
Feasible to prescribe ART to emergency department patients with suspected acute HIV infection

Empiric antiretroviral therapy (ART) for individuals presenting to emergency departments with suspected acute HIV infection (AHI) is highly feasible, investigators report in the July 1st edition of the

Published
08 July 2016
By
Michael Carter
New integrase inhibitor bictegravir looks promising in early studies

Gilead Sciences' novel integrase inhibitor bictegravir (formerly GS-9883) demonstrated favourable pharmacokinetics, good tolerability, an improved resistance profile compared to older drugs in its class, and potent antiviral activity

Published
06 July 2016
By
Liz Highleyman
Atripla three times weekly maintains HIV viral suppression for 24 weeks

People with undetectable viral load who switched from taking the Atripla single-tablet regimen (efavirenz/tenofovir/emtricitabine) every day to just every other weekday were able to maintain viral suppression

Published
05 July 2016
By
Liz Highleyman
The HIV Treatment Pipeline

“Depending on when you test positive for HIV, you could be looking at up to eight decades of treatment,” says Tim Horn of Treatment Action Group. “We need drugs that are gentler, kinder, better and cheaper.”

Published
28 June 2016
From
Poz
Antiretrovirals: A Success Story

Celebrating 20 years of effective HIV treatment - how antiretrovirals have improved since 1996 and the developments we still need.

Published
28 June 2016
From
Poz
PRO 140 antibody injections maintain viral suppression in phase 2 study

Subcutaneous injections of PRO 140, a monoclonal antibody that blocks HIV entry into cells, was well tolerated and maintained undetectable viral load for more than a year after

Published
28 June 2016
By
Liz Highleyman

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close